Although the IRD patient population is small compared with other retinal conditions, the research on novel therapeutic approaches is not.

Here, we report results of the first-in-human clinical trial (NCT04722107) of gene therapy for Bietti crystalline corneoretinal dystrophy

Natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy.

Usher Syndrome Coalition announces partnership with ProQR to support clinical trial enrollment for a potential therapy for USH2A.

The first patients have been dosed in the phase 2/3 Sirius and Celeste clinical trials investigating QR-421a in patients with USH2A.

ProQR news – Positive results achieved in our ongoing Usher syndrome and retinitis pigmentosa research.

RPE65-related LCA pivotal trials, . . . have paved the way for a new era of genetic treatments in ophthalmology.